Free Trial

Boston Scientific (BSX) Stock Price, News & Analysis

Boston Scientific logo
$91.45 +1.28 (+1.42%)
(As of 12:50 PM ET)

About Boston Scientific Stock (NYSE:BSX)

Key Stats

Today's Range
$90.28
$91.60
50-Day Range
$82.52
$90.45
52-Week Range
$53.93
$91.60
Volume
1.41 million shs
Average Volume
6.07 million shs
Market Capitalization
$134.78 billion
P/E Ratio
75.58
Dividend Yield
N/A
Price Target
$93.39
Consensus Rating
Moderate Buy

Company Overview

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
92nd Percentile Overall Score

BSX MarketRank™: 

Boston Scientific scored higher than 92% of companies evaluated by MarketBeat, and ranked 105th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Boston Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 19 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Boston Scientific has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Boston Scientific's stock forecast and price target.
  • Earnings Growth

    Earnings for Boston Scientific are expected to grow by 10.57% in the coming year, from $2.46 to $2.72 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Boston Scientific is 74.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.26.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Boston Scientific is 74.52, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.86.

  • Price to Earnings Growth Ratio

    Boston Scientific has a PEG Ratio of 2.66. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Boston Scientific has a P/B Ratio of 6.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Boston Scientific's valuation and earnings.
  • Percentage of Shares Shorted

    0.88% of the outstanding shares of Boston Scientific have been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently increased by 14.15%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Boston Scientific does not currently pay a dividend.

  • Dividend Growth

    Boston Scientific does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.88% of the outstanding shares of Boston Scientific have been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently increased by 14.15%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Boston Scientific has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 43 news articles for Boston Scientific this week, compared to 18 articles on an average week.
  • Search Interest

    27 people have searched for BSX on MarketBeat in the last 30 days. This is an increase of 42% compared to the previous 30 days.
  • MarketBeat Follows

    23 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 28% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,196,718.00 in company stock.

  • Percentage Held by Insiders

    Only 0.50% of the stock of Boston Scientific is held by insiders.

  • Percentage Held by Institutions

    89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Boston Scientific's insider trading history.
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Stock News Headlines

Piper Sandler Releases a Buy Rating on Boston Scientific (BSX)
Trump won. Buy this coin now.
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
See More Headlines

BSX Stock Analysis - Frequently Asked Questions

Boston Scientific's stock was trading at $57.81 on January 1st, 2024. Since then, BSX shares have increased by 56.0% and is now trading at $90.17.
View the best growth stocks for 2024 here
.

Boston Scientific Co. (NYSE:BSX) released its quarterly earnings results on Wednesday, October, 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. The company's revenue was up 19.3% compared to the same quarter last year.
Read the conference call transcript
.

Boston Scientific subsidiaries include VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and more.

Top institutional investors of Boston Scientific include FMR LLC (9.17%), State Street Corp (4.26%), Primecap Management Co. CA (2.57%) and Wellington Management Group LLP (2.23%). Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Jeffrey B Mirviss, John Bradley Sorenson, Edward J Ludwig, Edward J Ludwig, Jonathan Monson, Wendy Carruthers, Eric Francis Yves Thepaut, Vance R Brown, Nelda J Connors, Arthur C Butcher, Charles J Dockendorff, Ian T Meredith, David A Pierce and Scott Olson.
View institutional ownership trends
.

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include BlackRock (BLK), Broadcom (AVGO), ServiceNow (NOW), UnitedHealth Group (UNH), The Goldman Sachs Group (GS), NVIDIA (NVDA) and Illinois Tool Works (ITW).

Company Calendar

Last Earnings
10/23/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
1/29/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
10113710
Employees
48,000
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$93.39
High Stock Price Target
$110.00
Low Stock Price Target
$68.00
Potential Upside/Downside
+2.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
23 Analysts

Profitability

Net Income
$1.59 billion
Pretax Margin
13.84%

Debt

Sales & Book Value

Annual Sales
$14.24 billion
Cash Flow
$2.94 per share
Book Value
$14.22 per share

Miscellaneous

Outstanding Shares
1,473,830,000
Free Float
1,466,458,000
Market Cap
$134.78 billion
Optionable
Optionable
Beta
0.79

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSE:BSX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners